The upregulated expression of several FGF ligand genes after palbociclib + fulvestrant treatment prompted us to analyze the changes in the dependency of cancer cells on FGF signaling, with or without prior palbociclib + fulvestrant treatment, in the five established PDX models of ER+ breast cancer. This evidence concerns the gene ESR1 and cancer.